May 5 (Reuters) - Vertex Pharmaceuticals VRTX.O missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis $(CF)$ drug Trikafta.

However, the drugmaker raised the lower end of its revenue forecast as it looks to its acute pain drug, Journavx, and newer CF drugs to drive growth beyond its established line of treatments.

In December, the U.S. Food and Drug Administration approved Vertex's next-generation treatment, Alyftrek. This once-daily treatment for a rare and progressive genetic disease further strengthens Vertex's market dominance in CF treatments.

CF is an inherited disorder resulting from the absence of a specific protein, which disrupts the movement of salt and water in and out of cells in various organs.

In the first quarter ended March 31, sales of the company's older CF treatment, Trikafta, rose 2% to $2.53 billion but missed analysts' average expectation of $2.58 billion, according to LSEG data.

Vertex has activated more than 65 authorized treatment centers globally and 90 patients have begun cell collection for its gene therapy Casgevy, which treats a rare blood disorder that requires regular blood transfusions.

Vertex, sees 2025 revenue between $11.85 billion and $12 billion, compared to the previously projected range of $11.75 billion to $12 billion.

Total quarterly revenue rose 2.7% to $2.77 billion, missing analysts' estimates of $2.85 billion.

On an adjusted basis, the company reported a profit of $4.06 per share for the quarter, compared with analysts' expectations of a profit of $4.32.

(Reporting by Sriparna Roy and Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi)

((Sriparna.Roy@thomsonreuters.com;))